These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

282 related items for PubMed ID: 32810261

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Oxalobacter formigenes treatment combined with intensive dialysis lowers plasma oxalate and halts disease progression in a patient with severe infantile oxalosis.
    Pape L, Ahlenstiel-Grunow T, Birtel J, Krohne TU, Hoppe B.
    Pediatr Nephrol; 2020 Jun; 35(6):1121-1124. PubMed ID: 32107618
    [Abstract] [Full Text] [Related]

  • 3. A randomised Phase I/II trial to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria.
    Hoppe B, Niaudet P, Salomon R, Harambat J, Hulton SA, Van't Hoff W, Moochhala SH, Deschênes G, Lindner E, Sjögren A, Cochat P.
    Pediatr Nephrol; 2017 May; 32(5):781-790. PubMed ID: 27924398
    [Abstract] [Full Text] [Related]

  • 4. Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial.
    Michael M, Groothoff JW, Shasha-Lavsky H, Lieske JC, Frishberg Y, Simkova E, Sellier-Leclerc AL, Devresse A, Guebre-Egziabher F, Bakkaloglu SA, Mourani C, Saqan R, Singer R, Willey R, Habtemariam B, Gansner JM, Bhan I, McGregor T, Magen D.
    Am J Kidney Dis; 2023 Feb; 81(2):145-155.e1. PubMed ID: 35843439
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of Oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria.
    Hoppe B, Groothoff JW, Hulton SA, Cochat P, Niaudet P, Kemper MJ, Deschênes G, Unwin R, Milliner D.
    Nephrol Dial Transplant; 2011 Nov; 26(11):3609-15. PubMed ID: 21460356
    [Abstract] [Full Text] [Related]

  • 10. Plasma calcium oxalate supersaturation in children with primary hyperoxaluria and end-stage renal failure.
    Hoppe B, Kemper MJ, Bökenkamp A, Portale AA, Cohn RA, Langman CB.
    Kidney Int; 1999 Jul; 56(1):268-74. PubMed ID: 10411702
    [Abstract] [Full Text] [Related]

  • 11. Oxalobacter formigenes: a potential tool for the treatment of primary hyperoxaluria type 1.
    Hoppe B, Beck B, Gatter N, von Unruh G, Tischer A, Hesse A, Laube N, Kaul P, Sidhu H.
    Kidney Int; 2006 Oct; 70(7):1305-11. PubMed ID: 16850020
    [Abstract] [Full Text] [Related]

  • 12. Plasma oxalate levels in primary hyperoxaluria type I show significant intra-individual variation and do not correlate with kidney function.
    Hillebrand P, Hoppe B.
    Pediatr Nephrol; 2020 Jul; 35(7):1227-1233. PubMed ID: 32274573
    [Abstract] [Full Text] [Related]

  • 13. Sel1-like proteins and peptides are the major Oxalobacter formigenes-derived factors stimulating oxalate transport by human intestinal epithelial cells.
    Arvans D, Chang C, Alshaikh A, Tesar C, Babnigg G, Wolfgeher D, Kron S, Antonopoulos D, Bashir M, Cham C, Musch M, Chang E, Joachimiak A, Hassan H.
    Am J Physiol Cell Physiol; 2023 Jul 01; 325(1):C344-C361. PubMed ID: 37125773
    [Abstract] [Full Text] [Related]

  • 14. Enteric oxalate elimination is induced and oxalate is normalized in a mouse model of primary hyperoxaluria following intestinal colonization with Oxalobacter.
    Hatch M, Gjymishka A, Salido EC, Allison MJ, Freel RW.
    Am J Physiol Gastrointest Liver Physiol; 2011 Mar 01; 300(3):G461-9. PubMed ID: 21163900
    [Abstract] [Full Text] [Related]

  • 15. Primary hyperoxaluria: clinical course, diagnosis, and treatment after kidney failure.
    Raju DL, Cantarovich M, Brisson ML, Tchervenkov J, Lipman ML.
    Am J Kidney Dis; 2008 Jan 01; 51(1):e1-5. PubMed ID: 18155525
    [Abstract] [Full Text] [Related]

  • 16. A test of the hypothesis that oxalate secretion produces proximal tubule crystallization in primary hyperoxaluria type I.
    Worcester EM, Evan AP, Coe FL, Lingeman JE, Krambeck A, Sommers A, Phillips CL, Milliner D.
    Am J Physiol Renal Physiol; 2013 Dec 01; 305(11):F1574-84. PubMed ID: 24089413
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Lumasiran: A Review in Primary Hyperoxaluria Type 1.
    Kang C.
    Drugs; 2024 Feb 01; 84(2):219-226. PubMed ID: 38252335
    [Abstract] [Full Text] [Related]

  • 19. Oxalobacter formigenes colonization normalizes oxalate excretion in a gastric bypass model of hyperoxaluria.
    Canales BK, Hatch M.
    Surg Obes Relat Dis; 2017 Jul 01; 13(7):1152-1157. PubMed ID: 28552742
    [Abstract] [Full Text] [Related]

  • 20. Recovery From Dialysis in Patients With Primary Hyperoxaluria Type 1 Treated With Pyridoxine: A Report of 3 Cases.
    Lorenz EC, Lieske JC, Seide BM, Olson JB, Mehta R, Milliner DS.
    Am J Kidney Dis; 2021 May 01; 77(5):816-819. PubMed ID: 32891627
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.